Diego Enrico

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Fernanda Mosele, Bojana Stefanovska, Amélie Lusque et al. · Annals of Oncology · 2020 · 320 citations · Full text

Medicine, Cancer Biology, Oncology +14

Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?

Diego Enrico, Angélo Paci, Nathalie Chaput et al. · Clinical Cancer Research · 2019 · 73 citations · Full text

Life Sciences, Immunology, Oncology +17

Cancer Treatment Adaptations in the COVID-19 Era

Federico Waisberg, Diego Enrico, Martín Ángel et al. · JCO Oncology Practice · 2020 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

Diego Enrico, Ludovic Lacroix, Jeanne Chen et al. · JTO Clinical and Research Reports · 2020 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report

Diego Enrico, Florencia Tsou, Greta Catani et al. · JTO Clinical and Research Reports · 2022 · 16 citations · Full text

Medicine, Genetics, Pharmacology +16